MA45234A - Anticorps anti-facteur xi de coagulation - Google Patents

Anticorps anti-facteur xi de coagulation

Info

Publication number
MA45234A
MA45234A MA045234A MA45234A MA45234A MA 45234 A MA45234 A MA 45234A MA 045234 A MA045234 A MA 045234A MA 45234 A MA45234 A MA 45234A MA 45234 A MA45234 A MA 45234A
Authority
MA
Morocco
Prior art keywords
antibody
coagulation factor
coagulation
factor
Prior art date
Application number
MA045234A
Other languages
English (en)
Inventor
Zhu Chen
Kenneth P Ellsworth
Vaishnavi Ganti
James Milligan
Elizabeth Oldham
Bianka Prinz
Dietmar Seiffert
Mohammad Tabrizifard
Original Assignee
Adimab Llc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc, Merck Sharp & Dohme filed Critical Adimab Llc
Publication of MA45234A publication Critical patent/MA45234A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
MA045234A 2016-06-14 2017-06-12 Anticorps anti-facteur xi de coagulation MA45234A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14

Publications (1)

Publication Number Publication Date
MA45234A true MA45234A (fr) 2019-04-17

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045234A MA45234A (fr) 2016-06-14 2017-06-12 Anticorps anti-facteur xi de coagulation

Country Status (28)

Country Link
US (6) US10676536B2 (fr)
EP (1) EP3469002A1 (fr)
JP (2) JP7022081B2 (fr)
KR (2) KR102218714B1 (fr)
CN (2) CN116425879A (fr)
AR (1) AR108717A1 (fr)
AU (3) AU2017286432B2 (fr)
BR (1) BR112018075858A2 (fr)
CA (2) CA3172367A1 (fr)
CL (2) CL2018003565A1 (fr)
CO (1) CO2018013434A2 (fr)
CR (1) CR20180583A (fr)
DO (1) DOP2018000284A (fr)
EA (1) EA201892716A1 (fr)
EC (1) ECSP18091593A (fr)
GE (1) GEP20227382B (fr)
IL (2) IL315266A (fr)
JO (1) JOP20180121A1 (fr)
MA (1) MA45234A (fr)
MX (2) MX2018015757A (fr)
MY (1) MY201852A (fr)
NI (1) NI201800134A (fr)
PE (1) PE20190416A1 (fr)
PH (1) PH12018502586A1 (fr)
SG (2) SG11201810763TA (fr)
TN (1) TN2018000417A1 (fr)
TW (2) TWI752964B (fr)
WO (1) WO2017218371A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
AR108717A1 (es) * 2016-06-14 2018-09-19 Merck Sharp & Dohme Anticuerpos antifactor de la coagulación xi
BR112019012667A2 (pt) 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
KR20230034361A (ko) * 2020-07-02 2023-03-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도
CN115803348A (zh) * 2020-07-03 2023-03-14 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
CN117480182A (zh) * 2021-02-09 2024-01-30 艾瑞克斯疗法有限公司 抗s100a4人源化抗体、用途和方法
WO2023098637A1 (fr) * 2021-11-30 2023-06-08 苏州康宁杰瑞生物科技有限公司 Méthode de prévention et/ou de traitement de maladies thromboemboliques
WO2024141099A1 (fr) * 2022-12-30 2024-07-04 甘李药业股份有限公司 Anticorps dirigé contre le facteur xi de coagulation et/ou un facteur de forme activé xia de celui-ci et son utilisation

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク，インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (fr) 1990-08-29 2007-04-03 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1135415B1 (fr) 1998-12-01 2010-08-11 Facet Biotech Corporation Anticorps anti-interferon gamma humanises
MXPA02008472A (es) 2000-03-03 2004-03-26 Cambridge Antibody Tech Anticuerpos humanos contra la eotaxina y su uso.
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
SG10201404744RA (en) 2003-07-15 2014-10-30 Medarex Llc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
MY157915A (en) 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP2439273B1 (fr) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques
ES2546333T3 (es) 2005-07-01 2015-09-22 E. R. Squibb & Sons, L.L.C. Anticuerpos monoclonales humanos para ligandos 1 (PD-L1) de muerte programada
WO2007067730A2 (fr) 2005-12-08 2007-06-14 Medarex, Inc. Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
PT1960434E (pt) 2005-12-08 2012-10-02 Medarex Inc Anticorpos monoclonais humanos para fucosil-gm1 e métodos para a utilização de anti-fucosil-gm1
KR20190082996A (ko) 2006-06-06 2019-07-10 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
RU2009107277A (ru) 2006-08-03 2010-09-10 Астразенека Аб (Se) АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2680741A1 (fr) 2007-03-22 2009-01-15 The Regents Of The University Of California Anticorps monoclonaux therapeutiques qui neutralisent les neurotoxines botuliniques
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
SG187477A1 (en) 2007-09-26 2013-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
EP3002298B1 (fr) 2007-11-21 2019-08-28 Oregon Health & Science University Anticorps monoclonaux anti-facteur xi et leurs procédés d'utilisation
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2009154461A1 (fr) 2008-06-19 2009-12-23 Prothix Bv Utilisation d’anticorps anti-facteurs xi pour prévenir la formation de thrombus
CA2732003A1 (fr) 2008-07-31 2010-02-04 James D. Marks Anticorps neutralisant des neurotoxines botuliniques
CA2742014A1 (fr) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Antagonistes du recepteur 3 de type toll
CA2742968C (fr) 2008-11-07 2020-06-09 Fabrus Llc Bibliotheques combinatoires d'anticorps et leurs utilisations
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
CA2747519C (fr) 2008-12-18 2019-04-02 Oregon Health & Science University Anticorps anti-fxi et procedes d'utilisation
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
CA2755133A1 (fr) 2009-03-20 2010-09-23 Amgen Inc. Inhibiteurs peptidiques de kv1.3 selectifs et puissants
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
PL2426148T3 (pl) 2009-04-27 2016-01-29 Kyowa Hakko Kirin Co Ltd Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
AU2010308030B2 (en) 2009-10-12 2014-05-29 Pfizer Inc. Cancer treatment
CA2780221A1 (fr) 2009-11-04 2011-05-12 Fabrus Llc Procedes pour l'optimisation d'anticorps basee sur la maturation d'affinite
EP2516624B1 (fr) 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Lignée cellulaire 3m
US20110244826A1 (en) * 2010-02-03 2011-10-06 Subramaniyan Krishnan Mobile communication plan offerings
BR112013001175A2 (pt) 2010-07-16 2017-07-04 Adimab Llc bibliotecas de anticorpos
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
EA029419B1 (ru) 2010-11-19 2018-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Нейтрализующие антитела против ccl20
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
JP6082997B2 (ja) 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体
WO2012168199A1 (fr) 2011-06-06 2012-12-13 Novo Nordisk A/S Anticorps thérapeutiques
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
PL2650310T3 (pl) 2012-04-13 2017-01-31 Rottapharm Biotech S.R.L. Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
KR102060376B1 (ko) 2012-05-10 2019-12-30 바이엘 파마 악티엔게젤샤프트 응고 인자 xi 및/또는 그의 활성화 형태 인자 xia에 결합할 수 있는 항체 및 그의 용도
JP6441792B2 (ja) 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
WO2014004549A2 (fr) 2012-06-27 2014-01-03 Amgen Inc. Protéines de liaison anti-mésothéline
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CN106232625B (zh) 2013-10-01 2020-04-24 免疫医疗有限公司 治疗和诊断过表达α-V-β-6的癌症的方法
JPWO2015141826A1 (ja) 2014-03-20 2017-04-13 国立感染症研究所長 Ｃ型肝炎ウイルスに対する感染阻害活性を有する抗体
KR101753553B1 (ko) 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
MX2017001531A (es) 2014-08-08 2017-05-15 Alector Llc Anticuerpos anti-trem2 y metodos de uso de los mismos.
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
EP3991748A3 (fr) 2015-04-07 2022-08-24 Alector LLC Anticorps anti-sortiline et leurs procédés d'utilisation
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325010B1 (fr) 2015-07-23 2023-06-21 The Regents of The University of California Anticorps anti-facteur de coagulation xia et leurs utilisations
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
MX2018008939A (es) 2016-01-22 2019-08-21 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulacion xi.
AR108717A1 (es) * 2016-06-14 2018-09-19 Merck Sharp & Dohme Anticuerpos antifactor de la coagulación xi
DK3515947T3 (da) 2016-09-20 2024-07-29 Aronora Inc Hidtil ukendte antistoffer mod faktor XI og anvendelser deraf

Also Published As

Publication number Publication date
JP7022081B2 (ja) 2022-02-17
ECSP18091593A (es) 2019-01-31
MX2018015757A (es) 2019-05-30
GEP20227382B (en) 2022-05-25
BR112018075858A2 (pt) 2019-04-02
SG11201810763TA (en) 2018-12-28
CR20180583A (es) 2019-07-02
IL315266A (en) 2024-10-01
US11512142B2 (en) 2022-11-29
US11661460B2 (en) 2023-05-30
AU2017286432B2 (en) 2020-09-24
MX2023012740A (es) 2024-02-23
KR20190018504A (ko) 2019-02-22
TN2018000417A1 (en) 2020-06-15
TWI802193B (zh) 2023-05-11
US11479615B2 (en) 2022-10-25
JOP20180121A1 (ar) 2018-12-12
PE20190416A1 (es) 2019-03-19
CL2018003565A1 (es) 2019-03-22
US20200308302A1 (en) 2020-10-01
CN116425879A (zh) 2023-07-14
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
WO2017218371A1 (fr) 2017-12-21
AR108717A1 (es) 2018-09-19
IL263272A (en) 2018-12-31
CA3025869A1 (fr) 2017-12-21
US20200255542A1 (en) 2020-08-13
CL2024000367A1 (es) 2024-08-23
AU2020210233A1 (en) 2020-08-20
JP2021101720A (ja) 2021-07-15
US11485794B2 (en) 2022-11-01
SG10202103120UA (en) 2021-05-28
CO2018013434A2 (es) 2018-12-28
JP2019521978A (ja) 2019-08-08
JP7277500B2 (ja) 2023-05-19
TW201802120A (zh) 2018-01-16
AU2017286432A1 (en) 2018-12-06
CN109476758A (zh) 2019-03-15
TW202214702A (zh) 2022-04-16
EP3469002A1 (fr) 2019-04-17
KR102379580B1 (ko) 2022-03-29
KR102218714B1 (ko) 2021-02-24
AU2020210233B2 (en) 2024-03-07
CA3172367A1 (fr) 2017-12-21
PH12018502586A1 (en) 2019-10-07
US20200270364A1 (en) 2020-08-27
MY201852A (en) 2024-03-20
NI201800134A (es) 2019-03-05
US20170355780A1 (en) 2017-12-14
EA201892716A1 (ru) 2019-05-31
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
DOP2018000284A (es) 2019-01-31
US20200317811A1 (en) 2020-10-08
TWI752964B (zh) 2022-01-21
KR20210021124A (ko) 2021-02-24

Similar Documents

Publication Publication Date Title
MA43660A (fr) Anticorps anti-facteur xi de coagulation
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
DK3625259T3 (da) Anti-sirpalpha-antistoffer
MA45234A (fr) Anticorps anti-facteur xi de coagulation
MA47268A (fr) Anticorps anti-gpc3
MA53297A (fr) Anticorps anti-icos
MA46057A (fr) Anticorps anti-ctla4
DK3411410T3 (da) Pd-1-antistoffer
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA46041A (fr) Anticorps anti-tim -3
MA47472A (fr) Anticorps
DK3344654T3 (da) Anti-lag-3-antistoffer
MA46272A (fr) Anticorps anti-cd27
MA40229A (fr) Anticorps anti-tau humanisés
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3471609T3 (da) Kvantitativ seismokardiografi
MA42843A (fr) Anticorps anti-cd115
MA44236A (fr) Anticorps anti-tgfbêta 2
DK3250593T3 (da) Anti-transthyretin-antistoffer
MA51554A (fr) Anticorps il-6 améliorés
MA51134A (fr) Anticorps anti-alpha-synucléine